Uniqure NV【0EE0】銘柄情報

Uniqure NV (0EE0) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

31.50

( - )

買値

31.50

売値

31.50

出来高

387

0.00 日の範囲 0.00

31.50 52 週間の範囲 31.50

時価総額

1.987B

前日終値

31.50

始値

時刻

100

27.365

(O)

最終取引時間

23:29:40

財務取引量

VWAP

平均取引量 (3 か月)

US$ 2,118,482

発行済株式数

63,067,485

配当利回り

PER

-7.59

1 株当たり利益 (EPS)

-3.49

歳入

18.09M

純利益

-208.87M

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene the... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands. 詳細を表示

セクター

業界

ウェブサイト

www.uniqure.com

本社

Amsterdam, Netherlands

設立

1998

Uniqure NV is listed in the sector of the ロンドン証券取引所 with ticker 0EE0. The last closing price for Uniqure NV was US$31.50. Over the last year, Uniqure NV shares have traded in a share price range of US$ 31.50 to US$ 31.50.

Uniqure NV currently has 63,067,485 shares in issue. The market capitalisation of Uniqure NV is US$1.99 billion. Uniqure NV has a price to earnings ratio (PE ratio) of -7.59.